(S1 (S (S (NP (NP (JJ Neoplastic) (NN transformation)) (PP (IN of) (NP (JJ ciliary) (NN body) (NN epithelium)))) (VP (VBZ is) (VP (VBN associated) (PP (IN with) (NP (NP (NN loss)) (PP (IN of) (NP (NN opticin) (NN expression)))))))) (. .)))
(S1 (S (NP (NP (NN BACKGROUND)) (: :) (S (NP (NN Opticin)) (VP (VBZ is) (NP (NP (DT a) (ADJP (RB recently) (VBN discovered)) (NN glycoprotein)) (ADJP (JJ present) (PP (ADVP (RB predominantly)) (IN in) (NP (DT the) (NN vitreous) (NN humour))))))) (. .))))
(S1 (S (S (S (NP (PRP It)) (VP (VBZ is) (VP (VP (VBN synthesised)) (CC and) (VP (VBN secreted) (PP (IN by) (NP (NP (NP (DT the) (JJ ciliary) (NN body) (NN epithelium)) (PRN (-LRB- -LRB-) (NP (NN CBE)) (-RRB- -RRB-))) (PP (IN from) (NP (NP (DT the) (NN initiation)) (PP (IN of) (NP (NN CBE) (NN development))) (PP (IN in) (NP (DT the) (NN embryo))))))))))) (, ,) (CC and) (S (NP (NN production)) (VP (VBZ continues) (PP (IN throughout) (NP (NN life)))))) (. .)))
(S1 (S (NP (NP (NN AIM)) (: :) (S (VP (TO To) (VP (VB determine) (SBAR (IN whether) (S (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NN ciliary) (NN body) (NNS tumours)))) (VP (VB synthesise) (S (NP (NN opticin)) (VP (TO to) (VP (VB characterise) (ADVP (RB further)) (NP (NP (PRP$ its) (NN role)) (PP (IN in) (NP (NP (JJ ciliary) (NN body) (NN health)) (CC and) (NP (NN disease)))))))))))))) (. .))))
(S1 (S (NP (NP (NNS METHODS)) (: :) (S (NP (NN Immunohistochemistry)) (VP (VBD was) (VP (VBN used) (S (VP (TO to) (VP (VB determine) (NP (NP (DT the) (NN distribution)) (PP (IN of) (NP (NN opticin))) (PP (PP (IN in) (NP (JJ normal) (JJ human) (NN CBE))) (, ,) (CC and) (PP (IN in) (NP (ADJP (ADJP (JJ hyperplastic)) (CC and) (ADJP (JJ neoplastic))) (NN CBE) (NNS lesions))))))))))) (. .))))
(S1 (S (NP (NP (NNS RESULTS)) (: :) (S (NP (NN Opticin)) (VP (VBD was) (VP (VBN immunolocalised) (PP (TO to) (NP (NP (DT the) (NP (JJ basal) (NN cell) (NN surface)) (CC and) (NP (NN basement) (NN membrane) (NN material))) (PP (IN of) (NP (NP (DT the) (JJ non-pigmented) (NNS CBE)) (PP (IN in) (NP (NP (CD nine) (NN donor) (NNS eyes)) (CONJP (RB as) (RB well) (IN as)) (NP (NP (CD four) (JJ hyperplastic) (NNS lesions)) (PP (IN of) (NP (NP (DT the) (NN CBE)) (PRN (-LRB- -LRB-) (NP (NN Fuchs) (POS 's) (NN adenoma)) (-RRB- -RRB-)))))))))))))) (. .))))
(S1 (S (S (PP (IN By) (NP (NN contrast))) (, ,) (NP (NP (NN none)) (PP (IN of) (NP (NP (NP (CD eight) (JJ neoplastic) (NNS lesions)) (PRN (-LRB- -LRB-) (NP (CD two) (NN adenoma) (CC and) (CD six) (NN adenocarcinoma)) (-RRB- -RRB-))) (PP (IN of) (NP (NN CBE)))))) (VP (VBN stained) (PP (IN for) (NP (NN opticin))))) (. .)))
(S1 (S (NP (NP (NN CONCLUSION)) (: :) (S (NP (DT The) (JJ present) (NN series)) (VP (VBZ supports) (NP (DT the) (NN theory) (SBAR (IN that) (S (NP (NN opticin)) (VP (VBZ is) (VP (VBN produced) (PP (IN by) (NP (NP (DT the) (JJ non-pigmented) (NN CBE)) (PP (IN throughout) (NP (JJ adult) (NN life)))))))))))) (. .))))
(S1 (S (S (NP (NP (NN Loss)) (PP (IN of) (NP (NN opticin) (NN expression))) (PP (IN by) (NP (DT this) (NN tissue)))) (VP (VP (VBZ is) (VP (VBN associated) (PP (IN with)))) (CC and) (VP (MD could) (VP (VB contribute) (PP (IN towards) (NP (JJ neoplastic) (NN transformation))))))) (. .)))
